Bolstering Discovery, Translation & Clinical Efficacy of CNS-Targeted Oligonucleotides

Harnessing Maturing Oligonucleotide Technologies to Unlock Undruggable CNS Targets with Enhanced RNA Chemistry & Innovative Delivery

Oligonucleotide R&D is accelerating, driven by advances in brain shuttle technologies, RNA chemistry, and growing clinical validation from leaders such as Alnylam PharmaceuticalsStoke Therapeutics, and Ionis Pharmaceuticals. At the same time, major investmentsincluding Novartis into Arrowhead PharmaceuticalsBiogen into City Therapeutics, and Roche into Manifold Biounderscore CNS as a key frontier for these technologies, unlocking previously undruggable targets.

Building on last year’s momentum, the 6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology, oligo chemistry, RNA science, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative, neuromuscular, rare, epileptic, and neurodevelopmental disorders.

This summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli LillyDyne Therapeutics, Creyon Bio, and more for three days of collaboration to accelerate RNA-targeted CNS therapies. 

Topic focused, efficient networking and knowledge sharing

Zhenjiu Liu, Principal Scientist, Alnylam

Alnylam 6th Oligonucleotides for CNS Summit 2026

All the talks were highly engaging and interesting. Good mix of science. Vendors were also interesting.

Andrew McCarthy, Oligo Data Science Leader, GSK

GSK 6th Oligonucleotides for CNS Summit 2026

The meeting was great for networking, the panelists and presenters were all high caliber and the ensuing discussions very informative

Fay Touti, Senior Director, Asset Discovery, Apellis

Apellis 6th Oligonucleotides for CNS Summit 2026

Explore the Full Event Guide

  • Explore 3 days of highly technical, data-driven discussions addressing the challenges unique to CNS development 
  • Preview 5+ sessions containing brand-new data  
  • Explore unmissable networking opportunities, including roundtable discussions and a poster session 
  • Preview the audience composition and seniority from last year’s event 
  • Share easily with your team to assess and mobilise interest  
Oligonucleotide brochure (1)

What To Expect

160+

Attendees from the Oligos for CNS Community

18+

World-Class Speakers

6+

Hours of Networking with Biopharma Leaders

5+

Sessions Containing New Data 

3

Days of Data-driven Content 

Official Partners

Oligonucleotide brochure (1)
Quick Download

Attending Companies Include

Alnylam - attending company for 6th Oligonucleotides for CNS Summit 2026
Denali- attending company for 6th Oligonucleotides for CNS Summit 2026
Arrowhead- attending company for 6th Oligonucleotides for CNS Summit 2026
Biogen- attending company for 6th Oligonucleotides for CNS Summit 2026
Stoke therapeutics- attending company for 6th Oligonucleotides for CNS Summit 2026
BMS- attending company for 6th Oligonucleotides for CNS Summit 2026
Grünenthal- attending company for 6th Oligonucleotides for CNS Summit 2026
IPFsummit-144-768x512-1

Join 160+ CNS Oligo Experts

Be part of leading discussions with your peers spanning end-to-end development of siRNAs, ASOs, aptamers and more.  

Maintain-Your-Competitive-Edge-768x512-1-1-1

Showcase Your Solutions

Align your brand with leading innovators and gain visibility in a space defined by active engagement and strategic partnerships. 

Network-With-Decision-Makers-768x512-1-1

Explore the Brand-New Agenda

Immerse in fresh data drops, breakthrough approaches in CNS delivery, and a program built to spark conversations.